Thursday, February 23, 2012

Amgen to Present at the Citi 2012 Global Healthcare Conference

THOUSAND OAKS, Calif., Feb. 23, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Citi 2012 Global Healthcare Conference on Tuesday, Feb. 28, 2012, at the Waldorf Astoria in New York City, beginning at 4:30 p.m. Eastern Standard Time.

Read the rest of this entry

Posted in Press Releases

Wednesday, February 15, 2012

Amgen and Micromet Announce Early Termination of HSR Waiting Period for Amgen's Acquisition of Micromet

THOUSAND OAKS, Calif., Feb. 15, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Micromet, Inc. (NASDAQ: MITI) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended (HSR), in connection with Amgen’s tender offer for Micromet, was terminated early on Feb. 14, 2012 by the U.S. Federal Trade Commission.  The waiting period was scheduled to expire on Feb. 17, 2012.

Read the rest of this entry

Posted in Press Releases

Tuesday, February 14, 2012

Amgen Names Michael Severino, M.D., Senior Vice President, Global Development and Corporate Chief Medical Officer

THOUSAND OAKS, Calif., Feb. 14, 2012 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that Michael Severino, M.D., has been named senior vice president, Global Development and Corporate Chief Medical Officer, effective immediately.  Severino, 46, formerly vice president, Global Development at Amgen, will replace Sean Harper, M.D. Harper, 49, was appointed Amgen’s executive vice president, Research and Development.

Read the rest of this entry

Posted in Press Releases

Monday, February 13, 2012

Amgen to Present at the Leerink Swann Global Healthcare Conference

THOUSAND OAKS, Calif., Feb. 13, 2012 /PRNewswire/—Amgen (NASDAQ:AMGN) will present at the Leerink Swann Global Healthcare Conference at 9:30 a.m. Eastern Standard Time on Thursday, Feb. 16, 2012, at the Waldorf Astoria Hotel in New York City.  Jonathan M. Peacock, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen’s website, www.amgen.com, under Investors.

Read the rest of this entry

Posted in Press Releases

Wednesday, February 08, 2012

Amgen to Discuss Application for New Use of XGEVA® (denosumab) at FDA Oncologic Drugs Advisory Committee Meeting

THOUSAND OAKS, Calif., Feb. 8, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will discuss the data from the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to treat men with castration-resistant prostate cancer (CRPC) at high risk of developing bone metastases (spread of cancer to the bone) at today’s meeting of the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC).

Read the rest of this entry

Posted in Press Releases